ADMA ADMA BIOLOGICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—
Margins
Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%
Returns
ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $510.17M | $426.45M |
| Cost of revenue | $217.41M | $206.90M |
| Gross profit | $292.76M | $219.55M |
| R&D expense | $4.76M | $1.81M |
| SG&A expense | $91.58M | $74.12M |
| Operating income | $191.44M | $138.98M |
| Interest expense | $7.11M | $13.93M |
| Pretax income | $182.66M | $125.71M |
| Income tax | $35.73M | -$71.96M |
| Net income | $146.93M | $197.67M |
| EBITDA | $199.44M | $146.68M |
| EPS (basic) | 0.62 | 0.85 |
| EPS (diluted) | 0.60 | 0.81 |
| Weighted avg. shares (diluted) | 244.90M | 243.34M |
| Balance sheet | ||
| Cash & equivalents | $87.63M | $103.15M |
| Receivables | $158.43M | $50.00M |
| Inventory | $206.47M | $170.24M |
| Current assets | $466.51M | $331.41M |
| PP&E, net | $65.06M | $54.71M |
| Goodwill | $3.53M | $3.53M |
| Intangibles | $632,000 | $460,000 |
| Total assets | $624.24M | $488.68M |
| Current liabilities | $69.54M | $55.54M |
| Short-term debt | $2.81M | $0 |
| Long-term debt | $69.33M | $72.34M |
| Total debt | $72.14M | $72.34M |
| Total liabilities | $146.92M | $139.66M |
| Shareholders' equity | $477.32M | $349.02M |
| Net debt | -$15.49M | -$30.81M |
| Shares outstanding | 237.87M | 236.62M |
| Cash flow statement | ||
| Operating cash flow | $50.40M | $118.67M |
| Capital expenditure | $22.57M | $8.23M |
| Free cash flow | $27.82M | $110.45M |
| Investing cash flow | -$21.89M | -$8.57M |
| Financing cash flow | -$44.02M | -$58.30M |
| Depreciation & amortization | $8.00M | $7.70M |
| Stock-based compensation | $20.03M | $13.62M |
| Share buybacks | $31.94M | $0 |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.